M. Ahmed

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

Michael L. Wang, R. Davis, Maria A. Rodriguez, 2020, Leukemia & lymphoma.

High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin

A. Kallianpur, J. Greer, M. Ahmed, 1999, Bone Marrow Transplantation.

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

Michael L. Wang, Y. Oki, F. Turturro, 2014, British journal of haematology.

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

Michael L. Wang, L. Fayad, J. Westin, 2019, Haematologica.

Management strategies and outcomes for very elderly patients with diffuse large B‐cell lymphoma

Michael L. Wang, Y. Oki, F. Turturro, 2016, Cancer.

Outcomes in Refractory Aggressive Diffuse Large B Cell Lymphoma (DLBCL): Results from the International SCHOLAR-1 Study

J. Cerhan, C. Gisselbrecht, M. Crump, 2016 .

Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.

Christine F. Wogan, Y. Oki, F. Turturro, 2015, International journal of radiation oncology, biology, physics.

SUVmax on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy

Michael L. Wang, Y. Oki, E. Rohren, 2014 .

IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO

F. Turturro, S. Huang, Suping Zhou, 2017 .

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.

R. Davis, Y. Oki, F. Turturro, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.